DE4138042C2 - Epothilones, their production processes and agents containing these compounds - Google Patents

Epothilones, their production processes and agents containing these compounds

Info

Publication number
DE4138042C2
DE4138042C2 DE19914138042 DE4138042A DE4138042C2 DE 4138042 C2 DE4138042 C2 DE 4138042C2 DE 19914138042 DE19914138042 DE 19914138042 DE 4138042 A DE4138042 A DE 4138042A DE 4138042 C2 DE4138042 C2 DE 4138042C2
Authority
DE
Germany
Prior art keywords
epothilones
methanol
strain
epothilone
irtran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE19914138042
Other languages
German (de)
Other versions
DE4138042A1 (en
Inventor
Gerhard Prof Dr Hoefle
Norbert Dr Bedorf
Klaus Dr Gerth
Hans Prof Dr Reichenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 38124 BRAUNSCHWEIG DE
Original Assignee
GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 38124 BRAUNSCHWEIG DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 38124 BRAUNSCHWEIG DE filed Critical GESELLSCHAFT fur BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 38124 BRAUNSCHWEIG DE
Priority to DE19914138042 priority Critical patent/DE4138042C2/en
Priority to AU29437/92A priority patent/AU2943792A/en
Priority to PCT/EP1992/002656 priority patent/WO1993010121A1/en
Publication of DE4138042A1 publication Critical patent/DE4138042A1/en
Application granted granted Critical
Publication of DE4138042C2 publication Critical patent/DE4138042C2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Description

Die Erfindung betrifft Epothilone der folgenden allgemeinen Formel:The invention relates to epothilones of the following general formula:

worin R¹ Wasserstoff, C₁- bis C₄-Alkyl, C₁- bis C₄-Acyl, Li⁺, K⁺, Na⁺, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R² Wasserstoff oder eine Methylgruppe darstellt.wherein R¹ is hydrogen, C₁ to C₄ alkyl, C₁ to C₄ acyl, Li⁺, K⁺, Na⁺, 1/2 Mg 2+ or 1/2 Ca 2+ and R² represents hydrogen or a methyl group.

Ferner betrifft die Erfindung ein Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: The invention further relates to an epothilone, characterized by one or more of the following parameters:  

C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 429.25 für (M-H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)C₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 429.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)

IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1 IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1

DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune AnfärbungDC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color

HPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmHPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Des weiteren betrifft die Erfindung ein Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: The invention further relates to an epothilone, characterized by one or more of the following parameters:  

C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)- C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -

UV (MeOH)λmax (log ε) = 210 (4.17); 249 (3.97)UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)

IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1 IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1

DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune AnfärbungDC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color

HPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmHPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Besonders bevorzugt sind Epothilone mit der folgenden StrukturformelEpothilones with the following structural formula are particularly preferred

worin R² Wasserstoff oder Methyl bedeutet. (Das Kohlenstoffatom der Methylgruppe wird als C27 bezeichnet). Ferner betrifft die Erfindung ein Verfahren zum Gewinnen von Epothilonen, insbesondere der vorstehend charakterisierten Epothilone, das dadurch gekennzeichnet ist, daß man den Stamm So ce90 DSM 6773wherein R² is hydrogen or methyl. (The carbon atom the methyl group is referred to as C27). Furthermore, the Invention a method for obtaining epothilones, in particular of the epothilones characterized above, which thereby is characterized in that the strain So ce90 DSM 6773

  • - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert,- in a carbon sources, nitrogen sources and mineral salts cultivated medium,
  • - entweder während der Kultivierung des Stammes oder anschließend ein Adsorberharz zusetzt,- either during the cultivation of the strain or afterwards adds an adsorber resin,
  • - die Fermenterbrühe abtrennt,- separates the fermenter broth,
  • - die Epothilone aus dem Adsorberharz eluiert und- the epothilones eluted from the adsorber resin and
  • - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Lösungsmittel(n) befreit,- the eluate directly or via further cleaning steps from freed from the solvent (s),
  • - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt.- And if necessary via high pressure / low pressure chromatography and / or recrystallization of the different epothilones purified and separated from each other.

Gegebenenfalls können die so gewonnenen Epothilone mit gängigen chemischen Verfahren weiter umgesetzt werden, z. B. mit Basen in die Alkali- und Erdalkalisalze überführt und gegebenenfalls weiter zu Ethern umgesetzt werden, oder sie können mit organischen Säuren in die entsprechenden Ester überführt werden.If necessary, the epothilones obtained in this way can be used with common chemical processes are further implemented, e.g. B. with bases in the alkali and alkaline earth metal salts are transferred and, if appropriate be further converted to ethers, or they can be organic Acids are converted into the corresponding esters.

Ferner betrifft die Erfindung Mittel für den Pflanzenschutz in Landwirtschaft, Forstwirtschaft und/oder Gartenbau, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n). The invention further relates to agents for crop protection in agriculture, forestry and / or horticulture from one or more of the epothilones listed above or containing one or more of these epothilones, in addition to one or more conventional carriers and / or diluents.  

Schließlich betrifft die Erfindung therapeutische Mittel, die insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsupression bewirken können, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).Finally, the invention relates to therapeutic agents who develop cytotoxic activities in particular and / or Can cause immunosuppression consisting of one or more the epothilones listed above or one or more containing these epothilones, next to one or several common carriers (s) and / or diluent (s).

Im folgenden wird die Erfindung anhand von Beispielen und experimentellen Daten näher erläutert.In the following the invention is illustrated by examples and experimental Data explained in more detail.

ProduktionsstammProduction master

Stamm So ce90 wurde im Juli 1985 an der Gesellschaft für Biotechnologische Forschung (GBF) aus einer Bodenprobe von den Ufern des Zambesi, Südafrika, isoliert. Der Stamm ist bei der Deutschen Sammlung von Mikroorganismen (DSM) unter Nr. 6773 hinterlegt.Strain So ce90 was born in July 1985 at the Society for Biotechnological Research (GBF) a soil sample isolated from the banks of the Zambesi, South Africa. The tribe is with the German Collection of microorganisms (DSM) deposited under No. 6773.

Stammkultur und morphologische Beschreibung: Der Stamm wächst auf Cellulose als einziger Kohlenstoff- und Energiequelle mit KNO₃ als einzige Stickstoffquelle, z. B. auf Filterpapier über ST21 Mineralsalzagar (0.1% KNO₃; 0.1% MgSO₄ × 7 H₂O; 0.1% CaCl₂ × 2 H₂O; 0.1% K₂HPO₄; 0.01% MnSO₄ × 7 H₂O; 0.02% FeCl₃; 0.002% Hefeextrakt; Standard-Spurenelementlösung; 1% Agar). Auf diesem Medium werden dunkelrotbraune bis schwarzbraune Fruchtkörper gebildet, bestehend aus kleinen Sporangiolen (etwa 15 bis 30 µm Durchmesser) in mehr oder weniger großen dichten Haufen und Paketen.Strain culture and morphological description: The stem grows on cellulose as the only carbon and energy source with KNO₃ as the only nitrogen source, for. B. on filter paper over ST21 mineral salt agar (0.1% KNO₃; 0.1% MgSO₄ × 7 H₂O; 0.1% CaCl₂ × 2 H₂O; 0.1% K₂HPO₄; 0.01% MnSO₄ × 7 H₂O; 0.02% FeCl₃; 0.002% yeast extract; standard trace element solution; 1% agar). On this Medium dark red-brown to black-brown fruiting bodies are formed, consisting of small ones Sporangioles (about 15 to 30 µm in diameter) in more or less large dense piles and Packages.

Der Stamm wächst sehr gut mit Glucose und KNO₃, z. B. auf CA2-Agar (Grundmedium: 1.5 g Agar in 92 ml Aqua dest.; Stammlösung 1: 7.5% KNO₃, 7.5% K₂HPO₄ in Aqua dest,; Stammlösung 2: 1.5% MgSO₄ × 7 H₂O in Aqua dest.; Stammlösung 3: 0.2% CaCl₂ × 2 H₂O, 0.15% FeCl₃ in Aqua dest.; Stammlösung 4: 20% Glucose in Aqua dest. Die Stammlösungen werden durch Autoklavieren sterilisiert. Je 1 ml der Lösungen 1 bis 3, sowie 5 ml der Lösung 4 werden dem Grundmedium zugegeben, ebenso eine geeignete Menge einer Spurenelementlösung).The strain grows very well with glucose and KNO₃, e.g. B. on CA2 agar (basic medium: 1.5 g agar in 92 ml aqua dest .; Stock solution 1: 7.5% KNO₃, 7.5% K₂HPO₄ in distilled water ,; Stock solution 2: 1.5% MgSO₄ × 7 H₂O in aqua dest .; Stock solution 3: 0.2% CaCl₂ × 2 H₂O, 0.15% FeCl₃ in distilled water; Stock solution 4: 20% glucose in aqua dest. The stock solutions are made by autoclaving sterilized. 1 ml each of solutions 1 to 3 and 5 ml of solution 4 become the basic medium added, as well as a suitable amount of a trace element solution).

Die vegetativen Stäbchen haben die für Sorangium typische Form (relativ derbe, im Phasenkontrastmikroskop dunkle, zylindrische Stäbchen mit breit abgerundeten Enden, im Mittel 3-6 µm lang und 1 µm dick). Nach längerer Adaptation an das Wachstum in Flüssigmedien wächst der Stamm in homogener Zellsuspension. The vegetative rods have the shape typical of Sorangium (relatively coarse, in the phase contrast microscope dark, cylindrical rods with broadly rounded ends, on average 3-6 µm long and 1 µm thick). After a long adaptation to the growth in liquid media, the strain grows in homogeneous cell suspension.  

Der Stamm So ce90 produziert chemisch nahe verwandte Verbindungen, die antibiotische Aktivität besitzen. Insbesondere sind diese Verbindungen cytotoxisch sowie antifungal wirksam. Hervorzuheben ist z. B. die Hemmung von Mucor hiemalis.The So ce90 strain produces chemically closely related compounds, which have antibiotic activity. In particular are these compounds are cytotoxic and antifungal. To emphasize is z. B. the inhibition of Mucor hiemalis.

Produktion der biologisch aktiven VerbindungenProduction of the biologically active compounds

Die Verbindungen werden während der logarithmischen bis hin zur stationären Wachstumsphase produziert.The connections are made during the logarithmic to the stationary growth phase produced.

Eine typische Fermentation verläuft folgendermaßen: Ein 100 l-Fermenter wird mit 60 l Medium (0.8% Stärke; 0.2% Glucose; 0.2% Sojamehl; 0.2% Hefeextrakt; 0.1% CaCl₂×2H₂O; 0.1% MgSO₄ × 7 H₂O; 8 mg/l Fe-EDTA; pH 7.4) gefüllt. Beimpft wird mit 10 l einer im gleichen Medium jedoch zusätzlich mit 50 mM HEPES-Puffer pH 7.4 in Schüttelkolben angezogenen Vorkultur (160 upm, 30°C). Fermentiert wird bei 32°C mit einer Rührgeschwindigkeit von 500 upm und einer Belüftung von 0.2 NL pro m³ Reaktorvolumen und Std., der pH-Wert wird durch Zugabe von KOH bei 7.4 gehalten. Die Fermentation dauert 7-10 Tage . Die gebildeten aktiven Verbindungen befinden sich teils im Überstand und teils in den Zellen.A typical fermentation proceeds as follows: A 100 l fermenter is mixed with 60 l medium (0.8% Strength; 0.2% glucose; 0.2% soy flour; 0.2% yeast extract; 0.1% CaCl₂ × 2H₂O; 0.1% MgSO₄ × 7 H₂O; 8 mg / l Fe-EDTA; pH 7.4) filled. Inoculated with 10 l one in the same medium but also with 50 mM HEPES buffer pH 7.4 in pre-culture (160 rpm, 30 ° C) grown in shake flasks. It is fermented at 32 ° C with a stirring speed of 500 rpm and aeration of 0.2 NL  per m³ of reactor volume and hour, the pH is kept at 7.4 by adding KOH. The fermentation lasts 7-10 days. The active compounds formed are partly in the supernatant and partly in the cells.

Alternativ dazu kann in Gegenwart von Adsorberharzen (z. B. XAD-1180, Rohm und Haas, 2-5%) fermentiert werden.Alternatively, in the presence of adsorber resins (e.g. XAD-1180, Rohm and Haas, 2-5%) be fermented.

Isolierung von Epothilon A und BIsolation of epothilones A and B

Während der Fermentation von Sorangium cellulosum So ce90 (z. B. 70 l Fermentationsvolumen) in Gegenwart eines Adsorberharzes (z. B.: XAD-1180, Röhm und Haas, 2% v/v) werden die gebildeten Antibiotika Epothilon A und B vollständig an das Harz gebunden. Nach Abtrennung der Kulturbrühe (z. B. durch Absieben in einem Prozeßfilter) wird das Harz mit 3 Bettvolumen Wasser gewaschen und mit 4 Bettvolumen Methanol eluiert. Die vereinigten Eluate werden im Vakuum bis auf den Wassergehalt eingeengt und dreimal mit je 0,2 l Ethylacetat extrahiert. Die vereinigten Ethylacetatextrakte werden zur Trockne eingeengt (ca. 40 g Trockengewicht).During the fermentation of Sorangium cellulosum So ce90 (e.g. 70 l fermentation volume) in In the presence of an adsorber resin (e.g. XAD-1180, Röhm and Haas, 2% v / v) the formed Antibiotics Epothilon A and B fully bound to the resin. After separation the culture broth (e.g. by sieving in a process filter) the resin with 3 bed volumes of water washed and eluted with 4 bed volumes of methanol. The combined eluates are vacuumed up to the water content was concentrated and extracted three times with 0.2 l of ethyl acetate. The United Ethyl acetate extracts are evaporated to dryness (approx. 40 g dry weight).

Der Rohextrakt wird in 50 ml Methanol aufgenommen und an Lichroprep® RP-18 25-40 µm (Säule: 400 × 100 mm; Fluß: 200 ml/min;) isokratisch mit Methanol/Wasser 6/4 chromatographiert. Die Epothilone enthaltenden Fraktionen (Rt ca. 95-125 min) werden durch RP-18 Niederdruckchromatographie aufgereinigt. (Säule 400 × 60; HD-Sil-18-20-60, Labomatic; Laufmittel: Methanol/Wasser 65/35; Fluß 25 ml/min; Rt Epothilon A: 140-165 min; Rt Epothilon B: 170-195 min).The crude extract is taken up in 50 ml of methanol and chromatographed on Lichroprep® RP-18 25-40 µm (column: 400 × 100 mm; flow: 200 ml / min;) with methanol / water 6/4. The fractions containing epothilones (R t approx. 95-125 min) are purified by RP-18 low pressure chromatography. (400 × 60 column; HD-Sil-18-20-60, Labomatic; mobile solvent: methanol / water 65/35; flow 25 ml / min; R t epothilone A: 140-165 min; R t epothilone B: 170- 195 min).

Die Feinreinigung der Epothilone erfolgt durch Kristallisation ausThe epothilones are purified by crystallization

  • 1. Epothilon A: Toluol/Ethylacetat = 3 : 21. Epothilon A: toluene / ethyl acetate = 3: 2
  • 2. Epothilon B: Ethylacetat2. Epothilon B: ethyl acetate

Epothilon AEpothilone A

C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 429.25 für (M-H)-
¹H-NMR-Daten s. Tab. 1
¹³C-NMR-Daten s. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune Anfärbung
HPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nmC₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 429.25 for (MH) -
1 H-NMR data s. Tab. 1
13 C NMR data see. Tab. 2
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Epothilon BEpothilon B

C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
¹H-NMR-Daten s. Tab. 1
¹³C-NMR-Daten s. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1
DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune Anfärbung
HPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
1 H-NMR data s. Tab. 1
13 C NMR data see. Tab. 2
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm

Tabelle 1 Table 1

¹H-NMR-Daten der Epothilone A und B 1 H NMR data of epothilones A and B

Tabelle 2 Table 2

¹³C-NMR-Daten der Epothilone A und B 13 C NMR data of epothilones A and B

Claims (7)

1. Epothilone der allgemeinen Formel: worin R¹ Wasserstoff, C₁- bis C₄-Alkyl, C₁- bis C₄-Acyl, Li⁺, K⁺, Na⁺, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R² Wasserstoff oder eine Methylgruppe darstellt.1. Epothilones of the general formula: wherein R¹ is hydrogen, C₁ to C₄ alkyl, C₁ to C₄ acyl, Li⁺, K⁺, Na⁺, 1/2 Mg 2+ or 1/2 Ca 2+ and R² represents hydrogen or a methyl group. 2. Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: C₂₆H₃₉NO₆S[493]
FAB-MS (neg. Ionen): 492.25 für (M-H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97)IR Film auf Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120°C, braune AnfärbungHPLC: Rt = 5,4 min
Säule: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm2. epothilone, characterized by one or more of the following parameters: C₂₆H₃₉NO₆S [493]
FAB-MS (neg. Ions): 492.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97) IR film on Irtran:
ν: 3429; 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1 DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown staining HPLC: R t = 5.4 min
Column: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm 3. Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter: C₂₇H₄₁NO₆S[507]
FAB-MS (neg. Ionen): 506.25 für (M-H)-
UV (MeOH)λmax (log ε) = 210 (4.17); 249 (3.97)IR Film auf Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1DC: RF = 0,75
DC-Alufolie 60 F₂₅₄, Merck; Laufmittel:
Dichlormethan/Methanol = 90 : 10
Detektion:
1. UV-Löschung bei 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzt auf 120°C, braune AnfärbungHPLC: Rt = 6,3 min
Säule: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Fluß: 1,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35
Detektor: UV 254 nm3. epothilone, characterized by one or more of the following parameters: C₂₇H₄₁NO₆S [507]
FAB-MS (neg. Ions): 506.25 for (MH) -
UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97) IR film on Irtran:
ν = 3400; 2958; 2931; 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1 DC: R F = 0.75
TLC aluminum foil 60 F₂₅₄, Merck; Eluent:
Dichloromethane / methanol = 90:10
Detection:
1. UV quenching at 254 nm
2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown staining HPLC: R t = 6.3 min
Column: 4 × 250 mm Lichrosorb® RP-18 7 µm;
Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65:35
Detector: UV 254 nm 4. Verfahren zum Herstellen von Epothilonen nach einem der voranstehenden Ansprüche, dadurch gekennzeichnet, daß man den Stamm So ce90
  • - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert,
  • - entweder während der Kultivierung des Stammes oder anschließend ein Adsorberharz zusetzt,
  • - die Fermenterbrühe abtrennt,
  • - die Epothilone aus dem Adsorberharz eluiert und
  • - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Lösungsmittel(n) befreit,
  • - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt.
4. A method for producing epothilones according to any one of the preceding claims, characterized in that the strain So ce90
  • - cultivated in a medium containing carbon sources, nitrogen sources and mineral salts,
  • - either during the cultivation of the strain or subsequently adding an adsorber resin,
  • - separates the fermenter broth,
  • - the epothilones eluted from the adsorber resin and
  • - the eluates are freed from the solvent (s) directly or through further cleaning steps,
  • - and, if necessary, the various epothilones are purified and separated from one another by means of high pressure / low pressure chromatography and / or recrystallization.
5. Mittel für den Pflanzenschutz in der Landwirtschaft und Forstwirtschaft und/oder im Gartenbau, bestehend aus einem oder mehreren Epothilonen gemäß einem der voranstehenden Ansprüche oder eines oder mehrerer dieser Epothilone enthaltend, neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).5. Means for plant protection in agriculture and Forestry and / or horticulture, consisting of one or several epothilones according to one of the preceding claims or containing one or more of these epothilones, in addition to one or more conventional carriers and / or Diluent (s). 6. Mittel nach Anspruch 5, dadurch gekennzeichnet, daß sie Fungizide oder Fungistatika sind.6. Composition according to claim 5, characterized in that it Are fungicides or fungistatic agents. 7. Therapeutische Mittel, die insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsuppression bewirken können, bestehend aus einem oder mehreren Epothilonen nach einem der Ansprüche 1 bis 3 oder diese Epothilone enthaltend, neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).7. Therapeutic agents, especially cytotoxic activities develop and / or cause immunosuppression, consisting from one or more epothilones according to one of the claims 1 to 3 or containing these epothilones, in addition to one or more conventional carriers and / or diluents.
DE19914138042 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds Expired - Lifetime DE4138042C2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE19914138042 DE4138042C2 (en) 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds
AU29437/92A AU2943792A (en) 1991-11-19 1992-11-19 Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents
PCT/EP1992/002656 WO1993010121A1 (en) 1991-11-19 1992-11-19 Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914138042 DE4138042C2 (en) 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds

Publications (2)

Publication Number Publication Date
DE4138042A1 DE4138042A1 (en) 1993-05-27
DE4138042C2 true DE4138042C2 (en) 1993-10-14

Family

ID=6445140

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19914138042 Expired - Lifetime DE4138042C2 (en) 1991-11-19 1991-11-19 Epothilones, their production processes and agents containing these compounds

Country Status (3)

Country Link
AU (1) AU2943792A (en)
DE (1) DE4138042C2 (en)
WO (1) WO1993010121A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7750164B2 (en) 1996-12-03 2010-07-06 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1186606E (en) * 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf DERIVATIVES OF THE EPOTILONE ITS PREPARATION AND UTILIZATION
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
NZ334821A (en) * 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19636343C1 (en) * 1996-08-30 1997-10-23 Schering Ag New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
WO1998022461A1 (en) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
JP2001513098A (en) * 1997-02-25 2001-08-28 ゲゼルシャフト フュア バイオテクノロギッシェ フォーシュンク エム ベー ハー（ゲー ベー エフ） Epothilone with modified side chains
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (en) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft NEW DERIVATIVES OF EPOTILONE, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL USE.
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
HUP0100582A3 (en) * 1997-12-04 2003-03-28 Bristol Myers Squibb Co A process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
HUP0101564A3 (en) * 1998-02-05 2002-06-28 Novartis Ag Compositions containing epothilone
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (en) * 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) * 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
DE19820599A1 (en) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh New epothilone derivatives useful as pharmaceuticals and in plant protection
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
ES2175575T3 (en) * 1998-08-05 2002-11-16 Biotechnolog Forschung Gmbh PHARMACEUTICAL AGENTS CONTAINING EPOTILONE N-OXIDE A AND / OR N-OXIDODE EPOTILONE B.
DE19848306A1 (en) * 1998-10-14 2000-04-20 Schering Ag High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100716272B1 (en) 1998-11-20 2007-05-09 코산 바이오사이언시즈, 인코포레이티드 Recombinant methods and materials for producing epothilone and epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
JP2002536450A (en) 1999-02-11 2002-10-29 シエーリング アクチエンゲゼルシャフト Epothilone derivatives, their production method and their use as medicaments
CZ301498B6 (en) 1999-02-22 2010-03-24 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modified epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
BR0009721A (en) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125893B1 (en) 1999-04-30 2006-10-24 Schering Ag 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
GB0003753D0 (en) * 2000-02-17 2000-04-05 Biochemie Gmbh Organic compounds
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU9187601A (en) 2000-09-22 2002-04-02 Biotechnolog Forschung Gmbh Triazolo-epothilones
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
NZ526870A (en) 2001-01-25 2005-11-25 Bristol Myers Squibb Co Methods of administering epothilone analogs for the treatment of cancer
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
BR0206511A (en) 2001-01-25 2003-10-21 Bristol Myeres Squibb Company Parenteral formulation for epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
IL157128A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
EP1385522B1 (en) 2001-02-27 2009-06-24 Novartis AG Combination comprising a signal transduction inhibitor and an epothilone derivative
CN1496256A (en) 2001-03-14 2004-05-12 ����˹�ж�-����˹˹������˾ Combination of EPOTHILONE analogs and chemotherapeutic agents for treatment of proliferative diseases
CA2449077A1 (en) 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TWI341728B (en) 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US6719540B2 (en) 2002-03-12 2004-04-13 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
PT1506203E (en) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU2003275068B2 (en) * 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
DE10344882A1 (en) 2003-09-26 2005-04-21 Morphochem Ag Komb Chemie New macrocycles for the treatment of cancer
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
DE10355223A1 (en) 2003-11-26 2005-06-30 Institut für Pflanzenbiochemie (IPB) New macrocycles for the treatment of cancer
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CN1312286C (en) * 2005-10-19 2007-04-25 华南理工大学 Method for highly-effective producing epothilone using myxobacteria sorangium cellulosum
EP1994412A2 (en) 2006-03-31 2008-11-26 Brystol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2010511408A (en) 2006-12-04 2010-04-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ Compositions and methods for treating cancer with CpG rich DNA and cupredoxins
CN101754969A (en) 2007-05-25 2010-06-23 百时美施贵宝公司 Processes for making epothilone compounds and analogs
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (en) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Functionalized solid polymer nanoparticles containing epothilones
CN101918400B (en) * 2008-02-01 2012-08-29 浙江海正药业股份有限公司 A method for the separation and purification of epothilones
CN101362784A (en) * 2008-10-06 2009-02-11 山东大学 Ebomycin glycosides compounds, composition using the same as activity component and use thereof
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US8618146B2 (en) 2011-01-03 2013-12-31 Dr. Reddy's Laboratories Limited Epothilone compound formulations
CN102863474A (en) 2011-07-09 2013-01-09 陈小平 Platinum compounds for treating cell proliferative diseases and preparation method and application thereof
CN102993239A (en) 2011-09-19 2013-03-27 陈小平 Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino
CN104768962B (en) 2012-11-17 2017-04-05 北京市丰硕维康技术开发有限责任公司 Leaving group is the platinum-like compounds of the malonate derivative containing amino or alkylamino
CN103145722B (en) * 2013-03-05 2015-12-02 福建省微生物研究所 A kind of method of high speed adverse current chromatogram separating-purifying ebormycine
WO2015024884A1 (en) * 2013-08-19 2015-02-26 Sandoz Ag Method for the purifiction of epothilones via crystallization

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750164B2 (en) 1996-12-03 2010-07-06 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8481575B2 (en) 1996-12-03 2013-07-09 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Also Published As

Publication number Publication date
DE4138042A1 (en) 1993-05-27
AU2943792A (en) 1993-06-15
WO1993010121A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
DE4138042C2 (en) Epothilones, their production processes and agents containing these compounds
EP1367057B1 (en) Epothilones E and F
WO1998013375A1 (en) Compounds with antimycotic and cytostatic effect, preparation method, agent containing these compounds and dsm 11 092
DE3875792T2 (en) NEW HERBICIDE, ITS PRODUCTION AND USE.
DE3888587T2 (en) AB-006 antibiotics and process for their preparation.
DE2124711A1 (en)
EP0342363A2 (en) Angucyclinones from streptomyces, process to obtain them and their use
EP0337152A1 (en) Furans and lactones from streptomycetes, process for their preparation and their use
DE68924991T2 (en) 2-pyranone derivative and process for its preparation.
DD202047A5 (en) PROCESS FOR PREPARING THE MAKROLIDE 20-DIHYDRO-20,23-DIDEOXYTYLONOLIDE
DE2921085C2 (en)
DE69214258T2 (en) Antibiotic AB-041 and process for its production
DE2849666A1 (en) METHOD OF PREPARATION OF ANTIBIOTIC C-15003 P 4
DE3823067A1 (en) Chemical compound with antibiotic activity and preparation process
DE19630980B4 (en) Etnangien, production, use and production strain sorangium cellulosum DSM 11 028
DE68903581T2 (en) AGRICULTURAL SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF.
EP1373245B1 (en) Intermediates for producing spinosyns
US5397570A (en) Antibiotics AB-023 and process for preparing them
DE4410449C2 (en) Melithiazoles A and B, manufacturing process, agents containing Melithiazol A and / or B and Melittangium lichenicola DSM 9004 with the ability to form Melithiazole A and B.
DE3922283C1 (en)
EP0339442A2 (en) Angucyclinones from streptomyces, process to obtain them and their use
DE69610150T2 (en) New fungicidal compounds LL-15G256g, d and e made by LL-15G256 (Hypoxylon oceanicum)
DE69316903T2 (en) SAINTOPINE DERIVATIVES
DE2659180C2 (en) Antibiotic derivative of the substance SF-1540 and process for its preparation
DE3840519A1 (en) NEW ANGUCYCLINONE FROM STREPTOMYCETES, PROCESS FOR THEIR PREPARATION AND THEIR USE

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
R071 Expiry of right